The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r/mCC): Interim results of RC48-C018.
 
Guangwen Yuan
No Relationships to Disclose
 
Guiling Li
No Relationships to Disclose
 
Qingshui Li
No Relationships to Disclose
 
Youzhong Zhang
No Relationships to Disclose
 
Ruifang An
No Relationships to Disclose
 
Jinwei Miao
No Relationships to Disclose
 
Keqiang Zhang
No Relationships to Disclose
 
Hongying Yang
No Relationships to Disclose
 
Yi Huang
No Relationships to Disclose
 
Ruixia Guo
No Relationships to Disclose
 
Li Sun
No Relationships to Disclose
 
An Lin
No Relationships to Disclose
 
Junying Tang
No Relationships to Disclose
 
Xiumin Li
No Relationships to Disclose
 
Jianming Ying
No Relationships to Disclose
 
Yun Ling
No Relationships to Disclose
 
Yanan Wang
Employment - RemeGen Co., Ltd.
Travel, Accommodations, Expenses - RemeGen Co., Ltd.
 
Haiwen Zhou
Employment - RemeGen Co., Ltd.
Travel, Accommodations, Expenses - Remegen Co., Ltd.
 
Jianmin Fang
Employment - Remegen Co., Ltd.; Remegen Co., Ltd. (I)
Leadership - Remegen Co., Ltd.; Remegen Co., Ltd.
Stock and Other Ownership Interests - Remegen Co., Ltd.; Remegen Co., Ltd.
 
Lingying Wu
No Relationships to Disclose